Sagent Pharmaceuticals Company Profile (NASDAQ:SGNT)

About Sagent Pharmaceuticals

Sagent Pharmaceuticals logoSagent Pharmaceuticals, Inc. is a specialty and generic pharmaceutical company. The Company is a provider of pharmaceuticals to the hospital market, which it sells primarily throughout North America. It is focused on developing, manufacturing, sourcing and marketing injectable pharmaceutical products to the hospital market. It operates through two segments: Sagent US, consisting of the Company's operations in the United States and the Sagent (China) Pharmaceuticals Co. Ltd. (SCP) manufacturing facility, and Omega, which is focused on the Canadian and international markets. It offers a range of products across anti-infective, oncology and critical care indications in a range of presentations, including single and multi-dose vials, pre-filled ready-to-use syringes and premix bags. Its Sagent US product portfolio includes approximately 60 marketed products that it offers in over 180 presentations, and its Omega segment offers over 50 products.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drugs - Generic
  • Sub-Industry: Pharmaceuticals
  • Exchange: NASDAQ
  • Symbol: SGNT
  • CUSIP: 78669210
Key Metrics:
  • Previous Close: $0.00
  • 50 Day Moving Average: $21.72
  • 200 Day Moving Average: $15.37
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 29.77
  • P/E Growth: 0.00
  • Market Cap: $N/A
  • Beta: 1.66
Additional Links:
Companies Related to Sagent Pharmaceuticals:

Analyst Ratings

Consensus Ratings for Sagent Pharmaceuticals (NASDAQ:SGNT) (?)
Ratings Breakdown: 7 Hold Ratings
Consensus Rating:Hold (Score: 2.00)
Consensus Price Target: $17.55 (19.24% downside)

Analysts' Ratings History for Sagent Pharmaceuticals (NASDAQ:SGNT)
DateFirmActionRatingPrice TargetDetails
8/11/2016Deutsche Bank AGDowngradeBuy -> HoldView Rating Details
7/12/2016Raymond James Financial, Inc.DowngradeBuy -> Market PerformView Rating Details
7/11/2016Royal Bank Of CanadaDowngradeOutperform -> HoldView Rating Details
7/11/2016Piper Jaffray CompaniesDowngradeOverweight -> Neutral$22.00 -> $21.75View Rating Details
6/17/2016Jefferies Group LLCReiterated RatingHold$13.00 -> $15.00View Rating Details
6/1/2016J P Morgan Chase & CoReiterated RatingNeutralView Rating Details
5/9/2016Bank of America CorpReiterated RatingHold$13.00View Rating Details
(Data available from 2/23/2015 forward)


Earnings History for Sagent Pharmaceuticals (NASDAQ:SGNT)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/3/2016Q1$0.01($0.15)$74.30 million$67.30 millionViewN/AView Earnings Details
2/16/2016Q415($0.02)($0.55)$78.13 million$83.10 millionViewListenView Earnings Details
11/3/2015Q315($0.07)$0.01$73.84 million$75.20 millionViewN/AView Earnings Details
8/4/2015Q215$0.05($0.01)$83.28 million$77.30 millionViewN/AView Earnings Details
5/5/2015Q115$0.04$0.04$80.63 million$82.60 millionViewN/AView Earnings Details
2/19/2015Q414$0.01$0.91$76.20 million$84.40 millionViewN/AView Earnings Details
11/4/2014Q314($0.04)$0.08$64.01 million$65.40 millionViewN/AView Earnings Details
7/30/2014Q214($0.01)$0.09$67.14 million$69.20 millionViewListenView Earnings Details
5/6/2014Q114($0.02)$0.16$65.66 million$70.90 millionViewListenView Earnings Details
2/11/2014Q4($0.01)$0.11$60.25 million$64.10 millionViewListenView Earnings Details
11/5/2013($0.03)$0.10ViewN/AView Earnings Details
8/6/2013Q2 2013$0.46$59.27 million$59.60 millionViewN/AView Earnings Details
5/6/2013Q1 2013($0.03)$0.34$55.31 million$60.20 millionViewN/AView Earnings Details
11/8/2012Q312($0.20)($0.13)$48.60 million$49.40 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Sagent Pharmaceuticals (NASDAQ:SGNT)
Current Year EPS Consensus Estimate: $0.24 EPS
Next Year EPS Consensus Estimate: $0.73 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161$0.06$0.06$0.06
Q2 20161($0.19)($0.19)($0.19)
Q3 20161$0.19$0.19$0.19
Q4 20161$0.35$0.35$0.35
(Data provided by Zacks Investment Research)


Dividend History for Sagent Pharmaceuticals (NASDAQ:SGNT)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Sagent Pharmaceuticals (NASDAQ:SGNT)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
4/21/2016Ventures Fund V L.P. VivoMajor ShareholderSell2,005$13.55$27,167.75View SEC Filing  
11/4/2015Ventures Fund V L.P. VivoMajor ShareholderSell603,177$15.72$9,481,942.44View SEC Filing  
11/3/2015Vivo Ventures Vi, LlcMajor ShareholderSell67,283$16.32$1,098,058.56View SEC Filing  
11/2/2015Vivo Ventures Vi, LlcMajor ShareholderSell93,523$16.87$1,577,733.01View SEC Filing  
1/27/2015Morgan Stanley Investment ManaMajor ShareholderSell78,041$26.16$2,041,552.56View SEC Filing  
1/23/2015Morgan Stanley Investment ManaMajor ShareholderSell211,883$25.61$5,426,323.63View SEC Filing  
1/21/2015Morgan Stanley Investment ManaMajor ShareholderSell69,316$25.23$1,748,842.68View SEC Filing  
1/16/2015Morgan Stanley Investment ManaMajor ShareholderSell125,000$25.16$3,145,000.00View SEC Filing  
1/14/2015Morgan Stanley Investment ManaMajor ShareholderSell100,000$25.51$2,551,000.00View SEC Filing  
10/8/2014Robert J FlanaganDirectorSell16,000$31.56$504,960.00View SEC Filing  
10/7/2014Robert J FlanaganDirectorSell8,000$31.15$249,200.00View SEC Filing  
9/25/2014Robert J FlanaganDirectorSell16,000$30.01$480,160.00View SEC Filing  
9/24/2014Robert J FlanaganDirectorSell8,000$30.30$242,400.00View SEC Filing  
9/12/2014Robert J FlanaganDirectorSell16,000$28.30$452,800.00View SEC Filing  
9/11/2014Robert J FlanaganDirectorSell8,000$28.35$226,800.00View SEC Filing  
8/28/2014Robert J FlanaganDirectorSell16,000$27.19$435,040.00View SEC Filing  
8/27/2014Robert J FlanaganDirectorSell8,000$27.30$218,400.00View SEC Filing  
8/12/2014Robert J FlanaganDirectorSell16,000$24.39$390,240.00View SEC Filing  
7/31/2014Robert J FlanaganDirectorSell16,000$25.60$409,600.00View SEC Filing  
7/18/2014Robert J FlanaganDirectorSell16,000$26.18$418,880.00View SEC Filing  
7/2/2014Robert J FlanaganDirectorSell16,000$26.51$424,160.00View SEC Filing  
6/18/2014Robert J FlanaganDirectorSell16,000$23.37$373,920.00View SEC Filing  
6/4/2014Robert J FlanaganDirectorSell16,000$22.17$354,720.00View SEC Filing  
5/22/2014Robert FlanaganDirectorSell8,000$22.02$176,160.00View SEC Filing  
2/27/2014Michael LogerfoInsiderSell2,021$21.43$43,310.03View SEC Filing  
10/3/2013Morgan Stanley Investment Manamajor shareholderSell47,826$20.27$969,433.02View SEC Filing  
9/26/2013Morgan Stanley Investment Manamajor shareholderSell67,965$20.37$1,384,447.05View SEC Filing  
9/25/2013Morgan Stanley Investment Manamajor shareholderSell48,124$21.30$1,025,041.20View SEC Filing  
9/23/2013Morgan Stanley Investment Manamajor shareholderSell119,557$21.83$2,609,929.31View SEC Filing  
9/19/2013Morgan Stanley Investment Manamajor shareholderSell88,885$22.53$2,002,579.05View SEC Filing  
9/16/2013Frank KungDirectorSell1,161,717$21.25$24,686,486.25View SEC Filing  
9/16/2013Jeffrey YordonCEOSell85,813$20.03$1,718,834.39View SEC Filing  
9/16/2013Vivo Ventures Vi, Llcmajor shareholderSell622,700$21.25$13,232,375.00View SEC Filing  
8/12/2013Lorin DrakeVPSell1,000$23.69$23,690.00View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Sagent Pharmaceuticals (NASDAQ:SGNT)
News IconEarnings Parade Rolls On, What Are Analysts Saying About Sagent Pharmaceuticals, Inc. (NASDAQ:SGNT)? - Wall Street Beacon (NASDAQ:SGNT) - January 31 at 11:09 PM
News IconEarnings in Full Force, Analysts Take Aim at Sagent Pharmaceuticals, Inc. (NASDAQ:SGNT) - Wall Street Beacon (NASDAQ:SGNT) - January 26 at 4:51 AM
News IconSagent Pharmaceuticals, Inc. SGNT Medical Equipment Deals and Alliances Profile Prices from USD $250 (NASDAQ:SGNT) - January 24 at 1:09 AM
News IconWill The Needle Move For Sagent Pharmaceuticals, Inc. (NASDAQ:SGNT) Shares This Earnings Season? - Wall Street Beacon (NASDAQ:SGNT) - January 18 at 10:00 PM
News IconSagent Pharmaceuticals Inc SGNT Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 (NASDAQ:SGNT) - January 8 at 12:55 AM
News IconSagent Pharmaceuticals, Inc. SGNT Financial and Strategic SWOT Analysis Review Prices from USD $300 (NASDAQ:SGNT) - November 24 at 10:47 AM
News IconSagent Pharmaceuticals, Inc. (NASDAQ:SGNT) Latest Broker Coverage - NewsDen (NASDAQ:SGNT) - October 21 at 10:51 AM
News IconNWQ Bought 12 New Holdings in 2nd Quarter - Yahoo Sports (NASDAQ:SGNT) - September 16 at 7:00 PM logoNWQ Bought 12 New Holdings in 2nd Quarter (NASDAQ:SGNT) - September 16 at 7:00 PM logoForm 4 Sagent Pharmaceuticals, For: Aug 29 Filed by: Krizman Anthony (NASDAQ:SGNT) - September 1 at 7:13 PM
News IconNichi-Iko Pharmaceutical Co., Ltd. Announces Results of Tender Offer to Purchase All of the ... (NASDAQ:SGNT) - August 30 at 10:37 AM logoNichi-Iko Pharmaceutical Co., Ltd. (NASDAQ:SGNT) - August 30 at 10:37 AM logoNichi-Iko Pharmaceutical Co., Ltd. Announces Results of Tender Offer to Purchase All of the Outstanding Shares of Common Stock of Sagent Pharmaceuticals, Inc. (NASDAQ:SGNT) - August 29 at 7:14 PM logoSAGENT PHARMACEUTICALS, INC. Files SEC form 8-K, Completion of Acquisition or Disposition of Assets, Notice of Delist (NASDAQ:SGNT) - August 29 at 7:14 PM logoCan Sagent Pharmaceuticals, Inc. (NASDAQ:SGNT) Surprise Analysts This Quarter? - Investor Newswire (NASDAQ:SGNT) - August 29 at 11:54 AM logoBRIEF-Nichi-Iko Pharmaceutical fully buys Sagent Pharmaceuticals, Inc. via takeover bid (NASDAQ:SGNT) - August 28 at 10:24 PM logoSagent Pharmaceuticals, Inc. (NASDAQ:SGNT) Gets 0 Recommendations To Sell - Investor Newswire (NASDAQ:SGNT) - August 26 at 10:18 AM
News IconInvestor News: Lawsuit against Buyout of Sagent Pharmaceuticals Inc (NASDAQ:SGNT) filed (NASDAQ:SGNT) - August 23 at 11:53 AM
News IconInvestor News: Lawsuit against Buyout of Sagent Pharmaceuticals Inc (NASDAQ:SGNT) filed - GroundReport (NASDAQ:SGNT) - August 22 at 7:17 PM logoWill Sagent Pharmaceuticals, Inc. (NASDAQ:SGNT) Hit $21.75 Price Target? - Investor Newswire (NASDAQ:SGNT) - August 19 at 7:17 PM logoAnalysts See Sales Of $503.34 For Sagent Pharmaceuticals, Inc. (NASDAQ:SGNT) - Investor Newswire (NASDAQ:SGNT) - August 19 at 7:17 PM
News IconActive Watchful Movers- NetApp, Inc. (NASDAQ:NTAP), AT&T, Inc. (NYSE:T), Sagent Pharmaceuticals, Inc. (NASDAQ:SGNT) (NASDAQ:SGNT) - August 18 at 10:27 AM logoSagent Pharmaceuticals Initiates a Nationwide Voluntary Recall of Oxacillin for Injection, USP, 10 g due to presence of iron oxide particulate matter (NASDAQ:SGNT) - August 17 at 7:45 PM logoSAGENT PHARMACEUTICALS, INC. Financials (NASDAQ:SGNT) - August 16 at 7:30 PM logoLawsuit for Investors in Sagent Pharmaceuticals Inc (NASDAQ:SGNT) Against Buyout Filed (NASDAQ:SGNT) - August 15 at 7:47 PM logoSagent Pharmaceuticals, Inc. (NASDAQ:SGNT) Records An Estimated Annual Sales Mean Of $503.34 - Investor Newswire (NASDAQ:SGNT) - August 12 at 7:29 PM logoETF’s with exposure to Sagent Pharmaceuticals, Inc. : August 12, 2016 (NASDAQ:SGNT) - August 12 at 7:29 PM logoSagent Pharmaceuticals, Inc. :SGNT-US: Earnings Analysis: Q2, 2016 By the Numbers : August 10, 2016 (NASDAQ:SGNT) - August 10 at 7:54 PM logoGainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Sagent Pharmaceuticals, Inc. (SGNT) (NASDAQ:SGNT) - August 10 at 7:54 PM logoForm SC TO-T/A Sagent Pharmaceuticals, Filed by: Shepard Vision, Inc. (NASDAQ:SGNT) - August 9 at 7:41 PM logoNichi-Iko Pharmaceutical Co., Ltd. Announces Expiration of HSR Waiting Period for Proposed Acquisition of Sagent Pharmaceuticals, Inc. (NASDAQ:SGNT) - August 9 at 10:37 AM logoSAGENT PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly Report (NASDAQ:SGNT) - August 5 at 7:38 PM logoShepard Vision, Inc., a Wholly-Owned Subsidiary of … (NASDAQ:SGNT) - August 1 at 7:07 PM logoShepard Vision, Inc., a Wholly-Owned Subsidiary of Nichi-Iko Pharmaceutical Co., Ltd, Commences All-Cash … (NASDAQ:SGNT) - August 1 at 1:01 PM logoBRIEF-Shepard Vision commences all-cash tender offer of $21.75 net per share to buy shares of Sagent (NASDAQ:SGNT) - August 1 at 11:43 AM
News IconInvestor News: Buyout of Sagent Pharmaceuticals Inc (NASDAQ:SGNT) faces Investigation (NASDAQ:SGNT) - July 29 at 10:28 AM logoCan Shares Of Sagent Pharmaceuticals, Inc. (NASDAQ:SGNT) Hit $21.75? - Investor Newswire (NASDAQ:SGNT) - July 28 at 7:41 PM logoSapiens Names Andre M. Boisvert Chairman of Sapiens DECISION Board of Directors (NASDAQ:SGNT) - July 28 at 9:28 AM logoIs $21.75 Price Target Attainable For Sagent Pharmaceuticals, Inc. (NASDAQ:SGNT)? - Investor Newswire (NASDAQ:SGNT) - July 22 at 7:09 PM logoINVESTOR ALERT: The Law Offices of Vincent Wong Launches an Investigation of the Board of Directors of Sagent Pharmaceuticals, Inc. Concerning the Sale of the Company to Nichi-Iko Pharmaceutical Co., Ltd. (NASDAQ:SGNT) - July 22 at 11:48 AM logoAcquisition of Sagent Pharmaceuticals Inc (NASDAQ:SGNT) Under Investigation for Investors (NASDAQ:SGNT) - July 21 at 7:44 PM


What is Sagent Pharmaceuticals' stock symbol?

Sagent Pharmaceuticals trades on the NASDAQ under the ticker symbol "SGNT."

Where is Sagent Pharmaceuticals' stock going? Where will Sagent Pharmaceuticals' stock price be in 2017?

7 brokers have issued 1 year price objectives for Sagent Pharmaceuticals' shares. Their predictions range from $13.00 to $21.75. On average, they expect Sagent Pharmaceuticals' stock price to reach $17.55 in the next twelve months.

When will Sagent Pharmaceuticals announce their earnings?

Sagent Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, August, 8th 2016.

How do I buy Sagent Pharmaceuticals stock?

Shares of Sagent Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Sagent Pharmaceuticals stock cost?

One share of Sagent Pharmaceuticals stock can currently be purchased for approximately $21.73.

Sagent Pharmaceuticals (NASDAQ:SGNT) Chart for Thursday, February, 23, 2017

Institutional Ownership Chart

Institutional Ownership by Quarter for Sagent Pharmaceuticals (NASDAQ:SGNT)

Earnings History Chart

Earnings by Quarter for Sagent Pharmaceuticals (NASDAQ:SGNT)

Dividend History Chart

Dividend Payments by Quarter for Sagent Pharmaceuticals (NASDAQ:SGNT)

Last Updated on 2/23/2017 by Staff